ArticleOncotarget2020
Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer.
Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 48 citations in OpenAlex.
- Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate sacituzumab govitecan and TRAIL agonists in triple negative breast cancer.Breast cancer research : BCR · 2026Article
- TROP2 Is Uniformly Expressed in Primary Prostate Cancer but Frequently Reduced in Recurrent Disease.Cancers · 2026Article
- Understanding and Overcoming Antibody-Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Topoisomerase I inhibitor antibody-drug conjugates in breast cancer: the relevance of the DNA damage response to resistance, response, and combination treatment strategies.Breast cancer research and treatment · 2026Review
- Drug resistance to antibody-drug conjugates: mechanisms, challenges, and perspectives.Cancer biology & medicine · 2026Review
- Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody-drug conjugates.Antibody therapeutics · 2026Article
- Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer.Frontiers in immunology · 2026Article
- Sacituzumab tirumotecan in an advanced HR+/HER2-breast cancer patient with bone marrow metastasis-induced refractory thrombocytopenia: a case report and literature review.Frontiers in pharmacology · 2026Article
- Antibody-drug conjugates in triple-negative breast cancer (2010-2024): a bibliometric analysis of global trends and clinical translation.Discover oncology · 2025Article
- Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances.Journal of experimental & clinical cancer research : CR · 2025Review
- 177Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors.Molecular cancer therapeutics · 2025Article
- TROP2 expression and therapeutic targeting in uterine carcinosarcoma.Gynecologic oncology · 2025Article
- The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Resistance to antibody-drug conjugates: A review.Acta pharmaceutica Sinica. B · 2025Review
- Comparative immunohistochemical expression of TROP2 in brain metastatic and primary tumors.American journal of cancer research · 2025Article
- TROP2-targeted molecular imaging: a promising tool for precision oncology.American journal of nuclear medicine and molecular imaging · 2025Review
- Recent Advancements in Breast Cancer Therapies and Biomarkers: Mechanisms and Clinical Significance.Current pharmaceutical biotechnology · 2025Review
- Advances in adoptive cell therapies in small cell lung cancer.Exploration of targeted anti-tumor therapy · 2025Review
- Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer.iScience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of a humanized anti-Trop-2 IgG antibody conjugated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.